Phase II study of copanlisib in patients with tumors with PIK3CA mutations (PTEN loss allowed): NCI MATCH EAY131-Z1F.

Senthil Damodaran,Fengmin Zhao,Dustin A. Deming,Edith P. Mitchell,John J. Wright,Laurence A. Doyle,Robert Gray,Shuli Li,Lisa M. McShane,Larry Rubinstein,David R. Patton,Mickey Williams,Stanley R. Hamilton,Jennifer Marie Suga,Barbara A. Conley,Carlos L. Arteaga,Lyndsay Harris,Peter J. ODwyer,Alice P. Chen,Keith T. Flaherty

Phase II study of copanlisib in patients with tumors with PIK3CA mutations (PTEN loss allowed): NCI MATCH EAY131-Z1F.

2020

3506Background: The NCI-MATCH (EAY131) is a platform trial that enrolls patients (pts) with solid tumors, lymphomas, or multiple myeloma to targeted therapies based on matching genomic alterations ...

Keywords:

in patient
Pathology
Phases of clinical research
Copanlisib
PTEN
Cancer research
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations